We transform data into actionable insights to help you navigate the German healthcare market – the 4th largest in the world. With exclusive access to 18.6 million patients covered by our partner sickness funds, we can provide unique analyses tailored to your needs. Every month, we share key insights based on real patient data, helping you make informed decisions.
Want to see how our data can help you? Discover the possibilities with a free tailored ICD analysis below.
New!
Fact of the month!
facts – based on real data
May facts
How can pharmaceutical companies build early visibility and engagement with key decision-makers in Germany before formal benefit assessments?
"
"
From visibility to impact
After EMA approval, your product can be prescribed — but true success depends on early engagement. Reaching 90% of Germany’s drug experts through our trusted newsletter channel helps build awareness, gather insights, and drive uptake before AMNOG.
New!
Fact of the month!
facts – based on real data
May facts
How can pharmaceutical companies build early visibility and engagement with key decision-makers in Germany before formal benefit assessments?
"
"
From visibility to impact
After EMA approval, your product can be prescribed — but true success depends on early engagement. Reaching 90% of Germany’s drug experts through our trusted newsletter channel helps build awareness, gather insights, and drive uptake before AMNOG.
New!
Fact of the month!
facts – based on real data
May facts
How can pharmaceutical companies build early visibility and engagement with key decision-makers in Germany before formal benefit assessments?
"
"
From visibility to impact
After EMA approval, your product can be prescribed — but true success depends on early engagement. Reaching 90% of Germany’s drug experts through our trusted newsletter channel helps build awareness, gather insights, and drive uptake before AMNOG.
New!
Fact of the month!
facts – based on real data
May facts
How can pharmaceutical companies build early visibility and engagement with key decision-makers in Germany before formal benefit assessments?
"
"
From visibility to impact
After EMA approval, your product can be prescribed — but true success depends on early engagement. Reaching 90% of Germany’s drug experts through our trusted newsletter channel helps build awareness, gather insights, and drive uptake before AMNOG.
Germany is number one
pharmaceutical market in Europe
(and number four in the world)
8 reasons why
our platform for growth is unique
patientsbridge is part of the growth health group, headquartered in Germany – specialists in data-driven healthcare solutions and successful drug therapies. We work in partnership with the German healthcare system, providing access to real-world insights and sustainable networks that drive growth and therapeutic success.
Our mission is to support patients, prescribers, healthcare systems, and beyond – by offering innovative, data-backed solutions throughout the entire product lifecycle. From clinical trials and market launches to benefit assessments, pricing negotiations, and second-brand marketing strategies, our expertise ensures you stay ahead in a competitive market.
Germany, as the largest pharmaceutical market in Europe, is home of 80 million patients, of which we see about 20 million with our data partners–and whose therapies provide unparalleled insights. We’ll share exclusive facts and data monthly, offering unique perspectives to transform how you approach this dynamic market. These updates are designed to open doors to new opportunities and empower better healthcare decisions.
The growth health group delivers comprehensive, end-to-end solutions – from data intelligence and personalized strategies to effective communication channels. With patientsbridge, you’ll have a trusted partner bridging the gap between healthcare innovation and patient outcomes.
patientsbridge is part of the growth health group, headquartered in Germany – specialists in data-driven healthcare solutions and successful drug therapies. We work in partnership with the German healthcare system, providing access to real-world insights and sustainable networks that drive growth and therapeutic success.
Our mission is to support patients, prescribers, healthcare systems, and beyond – by offering innovative, data-backed solutions throughout the entire product lifecycle. From clinical trials and market launches to benefit assessments, pricing negotiations, and second-brand marketing strategies, our expertise ensures you stay ahead in a competitive market.
Germany, as the largest pharmaceutical market in Europe, is home of 80 million patients, of which we see about 20 million with our data partners–and whose therapies provide unparalleled insights. We’ll share exclusive facts and data monthly, offering unique perspectives to transform how you approach this dynamic market. These updates are designed to open doors to new opportunities and empower better healthcare decisions.
The growth health group delivers comprehensive, end-to-end solutions – from data intelligence and personalized strategies to effective communication channels. With patientsbridge, you’ll have a trusted partner bridging the gap between healthcare innovation and patient outcomes.
patientsbridge is part of the growth health group, headquartered in Germany – specialists in data-driven healthcare solutions and successful drug therapies. We work in partnership with the German healthcare system, providing access to real-world insights and sustainable networks that drive growth and therapeutic success.
Our mission is to support patients, prescribers, healthcare systems, and beyond – by offering innovative, data-backed solutions throughout the entire product lifecycle. From clinical trials and market launches to benefit assessments, pricing negotiations, and second-brand marketing strategies, our expertise ensures you stay ahead in a competitive market.
Germany, as the largest pharmaceutical market in Europe, is home of 80 million patients, of which we see about 20 million with our data partners–and whose therapies provide unparalleled insights. We’ll share exclusive facts and data monthly, offering unique perspectives to transform how you approach this dynamic market. These updates are designed to open doors to new opportunities and empower better healthcare decisions.
The growth health group delivers comprehensive, end-to-end solutions – from data intelligence and personalized strategies to effective communication channels. With patientsbridge, you’ll have a trusted partner bridging the gap between healthcare innovation and patient outcomes.